Paliperidone (9-hydroxyrisperidone) is the active ingredient in Invega extended-release tablets. Paliperidone is also the major active metabolite of Risperidone. Steady-state concentrations are typically attained within 4 to 5 days of dosing. Following daily administration of 12 mg extended release formulation, paliperidone steady state plasma concentrations ranged from 30 to 40 ng/mL.